Medical/Pharmaceuticals
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabol...
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway
Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings...
/C O R R E C T I O N -- CAIR/
In the news release, "EchoCare" Ultrasound Large Model Launched in Hong Kong as CAIR Showcases Large-Scale Ultrasound Dataset Training Achievements, issued 17-Sep-2025 by CAIR over PR Newswire, we are advised by the company that the headline, 2nd paragraph, 6th paragraph, and 7th paragraph have be...
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by Reme...
Sunway Medical Centre named Top Malaysian Smart Hospital in Newsweek's World's Best Smart Hospitals 2026 ranking
SUNWAY CITY, Malaysia, Sept. 18, 2025 /PRNewswire/ -- Sunway Medical Centre,
Sunway City (SMC) has been honoured as top Malaysian hospital and debuted in
the top 350 hospitals in the world, as per the latest Newsweek's World's Best
Smart Hospitals 2026 ranking.
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code...
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs)...
MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
* First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients. * Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of cir...
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile SKY-0515's Phase 2/3 FALCON-HD t...
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 /PRNewswire/ -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop2MW7141, a novel dual-target siRNA cand...
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)
* EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has ...
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results
* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoY * Maintained Positive Operating Cash Flow in the First Half of the Year SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a l...
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)
WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Türkiye İlaç ve ...
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA. Exosomes, as a next-generation bioactive carr...
Malaysia Healthcare Week Debuts in Kuwait, Strengthening Malaysia-Kuwait Medical Partnership
Spearheaded by the Malaysia Healthcare Travel Council, the event builds momentum towards the Malaysia Year of Medical Tourism 2026. KUWAIT CITY, Kuwait, Sept. 17, 2025 /PRNewswire/ -- Building on Malaysia's established reputation as a premier global healthcare destination and as part of the stra...
Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. - ASC30 tablet's higher efficacy is supported by its higher oral drug exposures. - ASC30 is safe and well tolerated with only mild-...
Genesis MedTech J-VALVE® TF Approved by NMPA, China's First Transfemoral TAVR for Aortic Regurgitation
Clinical data demonstrate low mortality, fewer complications and faster patient recovery with a minimally invasive alternative to open-heart surgery SINGAPORE, Sept. 17, 2025 /PRNewswire/ -- Genesis MedTech's structural heart subsidiary, Suzhou Jiecheng, has received approval fromChina's National...
EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts
PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that adults with atopic eczema (AE) are significantly more likely to experience suicidal thoughts. As one of the largest global inve...
New Scientific Review Highlights β-Lactoglobulin's Dual Benefits for Metabolic and Muscle Health
Emerging evidence positions this dairy protein as a powerful nutritional ingredient – and 21st.BIO's precision fermentation could make it more sustainable than ever. COPENHAGEN, Denmark, Sept. 16, 2025 /PRNewswire/ -- β-Lactoglobulin (BLG), the most abundant whey protein in cow's milk is drawing...
Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025
Lunit highlights global leadership in cancer AI alongside world health experts with dedicated APEC HLMHE session and WBS 2025 Leaders' Dialogue SEOUL, South Korea, Sept. 16, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announc...
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 327 media titles]
2026-03-27 11:15From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 301 media titles]
2026-03-31 13:53Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18New Swisslog APeC structure delivers greater resources to Southeast Asian customers
[Picked up by 288 media titles]
2026-03-31 11:25ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 280 media titles]
2026-03-25 16:51